Skip to main content

Table 1 Patient Demographics and MDS Disease Characteristics (N = 54)

From: Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra®, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome

Age (years)  
   Median 70
   Range 22–90
Age By Decade n (%)
   < 60 8 (15)
   61 – < 70 19 (35)
   70 – < 80 18 (33)
   ≥ 80 9 (17)
Gender  
   Male 35 (65)
   Female 19 (35)
Baseline Performance Status (ECOG)  
   0 18 (33)
   1 30 (56)
   2 4 (7)
   Unknown 2 (4)
Race  
   Caucasian 48 (88)
   Hispanic 3 (6)
   Asian 1 (2)
   Black 1 (2)
   Other 1 (2)
FAB Classification  
   RA 30 (56)
   RARS 9 (17)
   RAEB 9 (17)
   RAEB-t 3 (6)
   CMML 1 (2)
   Unknown 2 (4)
Baseline Karyotype  
   Abnormal 27 (50)
   Normal 27 (50)
IPSS Score  
   Low 39 (72)
   Intermediate 1 (2)
   High 12 (22)
   Unknown 2 (4)
Prior Therapy  
   Blood Product Support 41 (76)
   r-EPO 29 (54)
   G-CSF 8 (15)
   Steroids 6 (11)
   Thalidomide/Lenalidomide 10 (18)
   Other Chemotherapy 8 (15)
   5-Azacitadine 7 (13)
   Vitamins 3 (6)
   GM-CSF 1 (2)
Baseline Hematologic Values Median (Range)
   ANC 1.4 (0.0–27.3)
   HCT 27.0 (19.3–37.8)
   Hgb 9.1 (6.7–12.6)
   Platelet Count 70.0 (9.0–890)
  1. Abbreviations: RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; RAEB, refractory anemia with excess blasts; RAEB-t, refractory anemia with excess blasts in transformation; CMML, chronic myelomonocytic leukemia; IPSS, International Prognostic Scoring System; r-EPO, recombinant epoetin; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte macrophage colony stimulating factor; HCT, hematocrit; Hgb, hemoglobin.